Intestinal Research最新文献

{"title":"Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review.","authors":"Sung Wook Hwang,&nbsp;Min Kyu Kim,&nbsp;Mi-Na Kweon","doi":"10.5217/ir.2023.00019","DOIUrl":"10.5217/ir.2023.00019","url":null,"abstract":"<p><p>Immune checkpoint inhibitors have dramatically revolutionized the therapeutic landscape for patients with advanced malignancies. Recently, convincing evidence has shown meaningful influence of gut microbiome on human immune system. With the complex link between gut microbiome, host immunity and cancer, the variations in the gut microbiota may influence the efficacy of immune checkpoint inhibitors. Indeed, some bacterial species have been reported to be predictive for cancer outcome in patients treated with immune checkpoint inhibitors. Although immune checkpoint inhibitors are currently proven to be an effective anti-tumor treatment, they can induce a distinct form of toxicity, termed immune-related adverse events. Immune-related colitis is one of the common toxicities from immune checkpoint inhibitors, and it might preclude the cancer therapy in severe or refractory cases. The manipulation of gut microbiome by fecal microbiota transplantation or probiotics administration has been suggested as one of the methods to enhance anti-tumor effects and decrease the risk of immune-related colitis. Here we review the role of gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis to provide a new insight for better anti-cancer therapy.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":"433-442"},"PeriodicalIF":4.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10166090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis.","authors":"Jihun Jang,&nbsp;Jihye Park,&nbsp;Soo Jung Park,&nbsp;Jae Jun Park,&nbsp;Jae Hee Cheon,&nbsp;Tae Il Kim","doi":"10.5217/ir.2022.00139","DOIUrl":"10.5217/ir.2022.00139","url":null,"abstract":"<p><strong>Background/aims: </strong>Patients with more than 10 cumulative polyps might involve a greater genetic risk of colorectal neoplasia development. However, few studies have investigated the risk factors of polyposis recurrence and development of advanced neoplasms among patients with non-hereditary colorectal polyposis.</p><p><strong>Methods: </strong>This study included patients (n=855) with 10 or more cumulative polyps diagnosed at Severance Hospital from January 2012 to September 2021. Patients with known genetic mutations related to polyposis, known hereditary polyposis syndromes, insufficient information, total colectomy, and less than 3 years of follow-up were excluded. Finally, 169 patients were included for analysis. We collected clinical data, including colonoscopy surveillance results, and performed Cox regression analyses of risk factors for polyposis recurrence and advanced neoplasm development.</p><p><strong>Results: </strong>The 169 patients were predominantly male (84.02%), with a mean age of 64.19±9.92 years. The mean number of adenomas on index colonoscopy was 15.33±8.47. Multivariable analysis revealed history of cancer except colon cancer (hazard ratio [HR], 2.23; 95% confidence interval [CI], 1.23-4.01), current smoking (HR, 2.39; 95% CI, 1.17-4.87), and detection of many polyps (≥15) on index colonoscopy (HR, 2.05; 95% CI, 1.21-3.50) were significant risk factors for recurrence of polyposis. We found no statistically significant risk factors for advanced neoplasm development during surveillance among our cohort.</p><p><strong>Conclusions: </strong>The presence of many polyps (≥15) on index colonoscopy, history of cancer except colon cancer, and current smoking state were significant risk factors for polyposis recurrence among patients with non-hereditary colorectal polyposis.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":"510-517"},"PeriodicalIF":4.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9540282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of acute colonic diverticulitis in immunocompromised versus immunocompetent patients: a systematic review and meta-analysis.","authors":"Jae Gon Lee,&nbsp;Yong Eun Park,&nbsp;Ji Young Chang,&nbsp;Hyun Joo Song,&nbsp;Duk Hwan Kim,&nbsp;Young Joo Yang,&nbsp;Byung Chang Kim,&nbsp;Shin Hee Lee,&nbsp;Myung-Won You,&nbsp;Seong-Eun Kim","doi":"10.5217/ir.2023.00005","DOIUrl":"10.5217/ir.2023.00005","url":null,"abstract":"<p><strong>Background/aims: </strong>Immunocompromised patients with acute colonic diverticulitis are at high risk for complications and failure of non-surgical treatment. However, evidence on the comparative outcomes of immunocompromised and immunocompetent patients with diverticulitis is lacking. This systematic review and meta-analysis investigated the outcomes of medical treatment in immunocompromised and immunocompetent patients with diverticulitis.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane Library. Studies comparing the clinical outcomes of immunocompromised and immunocompetent patients with diverticulitis were included.</p><p><strong>Results: </strong>A total of 10 studies with 1,946,461 subjects were included in the quantitative synthesis. The risk of emergency surgery and postoperative mortality after emergency surgery was significantly higher in immunocompromised patients than in immunocompetent patients with diverticulitis (risk ratio [RR], 1.76; 95% confidence interval [CI], 1.31-2.38 and RR, 3.05; 95% CI, 1.70-5.45, respectively). Overall risk of complications associated with diverticulitis was non-significantly higher in immunocompromised than in immunocompetent patients (RR, 1.24; 95% CI, 0.95-1.63). Overall mortality irrespective of surgery was significantly higher in immunocompromised than in immunocompetent patients with diverticulitis (RR, 3.65; 95% CI, 1.73-7.69). By contrast, postoperative mortality after elective surgery was not significantly different between immunocompromised and immunocompetent patients with diverticulitis. In subgroup analysis, the risk of emergency surgery and recurrence was significantly higher in immunocompromised patients with complicated diverticulitis, whereas no significant difference was shown in mild disease.</p><p><strong>Conclusions: </strong>Immunocompromised patients with diverticulitis should be given the best medical treatment with multidisciplinary approach because they had increased risks of surgery, postoperative morbidity, and mortality than immunocompetent patients.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":"481-492"},"PeriodicalIF":4.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9533697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India.","authors":"Arshdeep Singh,&nbsp;Vandana Midha,&nbsp;Vikram Narang,&nbsp;Saurabh Kedia,&nbsp;Ramit Mahajan,&nbsp;Pavan Dhoble,&nbsp;Bhavjeet Kaur Kahlon,&nbsp;Ashvin Singh Dhaliwal,&nbsp;Ashish Tripathi,&nbsp;Shivam Kalra,&nbsp;Narender Pal Jain,&nbsp;Namita Bansal,&nbsp;Rupa Banerjee,&nbsp;Devendra Desai,&nbsp;Usha Dutta,&nbsp;Vineet Ahuja,&nbsp;Ajit Sood","doi":"10.5217/ir.2022.00087","DOIUrl":"10.5217/ir.2022.00087","url":null,"abstract":"<p><strong>Background/aims: </strong>Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Limited data exist on PSC in patients with IBD from India. We aimed to assess the prevalence and disease spectrum of PSC in Indian patients with IBD.</p><p><strong>Methods: </strong>Database of IBD patients at 5 tertiary care IBD centers in India were analyzed retrospectively. Data were extracted and the prevalence of PSC-IBD was calculated.</p><p><strong>Results: </strong>Forty-eight patients out of 12,216 patients with IBD (9,231 UC, 2,939 CD, and 46 IBD unclassified) were identified to have PSC, resulting in a prevalence of 0.39%. The UC to CD ratio was 7:1. Male sex and pancolitis (UC) or colonic CD were more commonly associated with PSC-IBD. The diagnosis of IBD preceded the diagnosis of PSC in most of the patients. Majority of the patients were symptomatic for liver disease at diagnosis. Eight patients (16.66%) developed cirrhosis, 5 patients (10.41%), all UC, developed malignancies (3 colorectal cancer [6.25%] and 2 cholangiocarcinoma [4.16%]), and 3 patients died (2 decompensated liver disease [4.16%] and 1 cholangiocarcinoma [2.08%]) on follow-up. None of the patients mandated surgical therapy for IBD.</p><p><strong>Conclusions: </strong>Concomitant PSC in patients with IBD is uncommon in India and is associated with lower rates of development of malignancies.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":"452-459"},"PeriodicalIF":4.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40714283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Not all acute colonic diverticulitis follows the same course: a potential risk for immunocompromised individuals.","authors":"Yehyun Park","doi":"10.5217/ir.2023.00142","DOIUrl":"10.5217/ir.2023.00142","url":null,"abstract":"","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":"21 4","pages":"415-417"},"PeriodicalIF":4.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71423564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the survey, to the ideal therapy for Asian.","authors":"Ki Jae Jo,&nbsp;Jong Pil Im","doi":"10.5217/ir.2023.00075","DOIUrl":"https://doi.org/10.5217/ir.2023.00075","url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 280 fections can be fatal for patients. Therefore, clinicians treating IBD must always be alert for infections. The main strategy to prevent infections is vaccination. In fact, clinical practice guidelines published by the European Crohn’s and Colitis Or­ ganisation and the American College of Gastroenterology stron­ gly recommend vaccination in patients with IBD. In addition, the global severe acute respiratory syndrome coronavirus 2 (SARS­CoV2) pandemic highlighted the importance of vacci­ nation in immunocompromised patients and in patients with underlying chronic diseases, such as IBD; Lee et al. strongly recommended SARS­CoV2 vaccination for the patients with IBD who are treated with immunosuppressants and biologic agents, since the benefits outweigh the risks. In patients with IBD, vaccines against viruses, such as hepa­ titis B virus, hepatitis A virus, influenza, and human papilloma­ virus, as well as vaccines against bacteria, such as pneumococ­ cus, are recommended. However, the timing of vaccinations is yet to be established. Mishra et al. reported that although hepatitis B virus vaccination in patients with ulcerative colitis showed a lower serologic response than in general population, an appropriate vaccine effect could be expected if they are not exposed to corticosteroid, immunosuppressant, or biologic agents. Therefore, several guidelines have suggested the tim­ ing of vaccination as either at diagnosis or just prior to starting the immunosuppressive therapy. Despite the need and recommendations for vaccination, it may not be implemented in practice for a variety of reasons. A survey of gastroenterologists’ practices regarding vaccination in patients with IBD in the United States reported that while pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2023.00075 Intest Res 2023;21(3):280-282","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":"21 3","pages":"280-282"},"PeriodicalIF":4.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/d8/ir-2023-00075.PMC10397544.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis.","authors":"Suprabhat Giri,&nbsp;Dhiraj Agrawal,&nbsp;Shivaraj Afzalpurkar,&nbsp;Sunil Kasturi,&nbsp;Amrit Gopan,&nbsp;Sridhar Sundaram,&nbsp;Aditya Kale","doi":"10.5217/ir.2022.00094","DOIUrl":"https://doi.org/10.5217/ir.2022.00094","url":null,"abstract":"<p><strong>Background/aims: </strong>The data on the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with inflammatory bowel disease (IBD) are conflicting. The present systematic review was thus conducted to study the prevalence of HBV and HCV markers in patients with IBD.</p><p><strong>Methods: </strong>A comprehensive literature search of 3 databases was conducted from 2000 to April 2022 for studies evaluating the prevalence of HBV or HCV in patients with IBD. Pooled prevalence rates across studies were expressed with summative statistics.</p><p><strong>Results: </strong>A total of 34 studies were included in the final analysis. The pooled prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B core antibodies were 3.3% and 14.2%, respectively. In HBsAg positive IBD patients, hepatitis B e antigen positivity and detectable HBV DNA were seen in 15.3% and 61.0% of patients, respectively. Only 35.6% of the IBD patients had effective HBV vaccination. The pooled prevalence of anti-HCV and detectable HCV RNA were 1.8% and 0.8%, respectively. The pooled prevalence of markers of HBV infection was higher in Asian studies, while the prevalence of markers of HCV infection was higher in European studies. The prevalence of viral hepatitis markers was similar between IBD patients and the general population and that between ulcerative colitis and Crohn's disease.</p><p><strong>Conclusions: </strong>The prevalence of markers of viral hepatitis remains same as the general population with significant regional variations, although the quality of evidence remains low due to publication bias. Only a small proportion of IBD patients had an effective HBV vaccination, requiring improvement in screening and vaccination practices.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":"21 3","pages":"392-405"},"PeriodicalIF":4.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/75/ir-2022-00094.PMC10397541.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9939684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.","authors":"Han Hee Lee,&nbsp;Jae Jun Park,&nbsp;Bo-In Lee,&nbsp;Ida Hilmi,&nbsp;Jose Sollano,&nbsp;Zhi Hua Ran","doi":"10.5217/ir.2023.00012","DOIUrl":"https://doi.org/10.5217/ir.2023.00012","url":null,"abstract":"<p><strong>Background/aims: </strong>Inflammatory bowel disease (IBD) is no longer a rare disease in Asia, thus it needs to prepare recommendations relevant to Asian patients. This study aimed to identify disparities in the process of the diagnosis of IBD in Asian countries/regions.</p><p><strong>Methods: </strong>In line with the 2020 Asian Organization for Crohn's and Colitis annual meeting, a multinational web-based survey about Asian physicians' perspectives on IBD was conducted.</p><p><strong>Results: </strong>A total of 384 Asian physicians (99 in China, 93 in Japan, 110 in Korea, and 82 in other Asian countries/regions) treating IBD patients from 24 countries/regions responded to the survey. Most respondents were gastroenterologists working in an academic teaching hospital. About half of them had more than 10 years of clinical experience in caring for patients with IBD. The European Crohn's Colitis Organisation guideline was used most commonly for the diagnosis of IBD except for Japanese physicians who preferred their own national guideline. The Mayo score and Crohn's Disease Activity Index were the most commonly used activity scoring systems for ulcerative colitis and Crohn's disease, respectively. Endoscopy, not surprisingly, was the main investigation in assessing the extent and activity of IBD. On the other hand, there were disparities across countries/regions with regard to the favored modalities of small bowel and perianal evaluation of Crohn's disease, as well as the use of serologic markers.</p><p><strong>Conclusions: </strong>Results of the present survey revealed practical behaviors of Asian physicians in the diagnosis of IBD. Investigating the reasons for different diagnostic approaches among countries/regions might help us develop Asian guidelines further.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":"21 3","pages":"328-338"},"PeriodicalIF":4.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/d1/ir-2023-00012.PMC10397551.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9992799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Submucosal fat accumulation in Crohn's disease: evaluation with sonography.","authors":"Tomás Ripollés,&nbsp;María Jesús Martínez-Pérez,&nbsp;José María Paredes,&nbsp;José Vizuete,&nbsp;Gregorio Martin,&nbsp;Lidia Navarro","doi":"10.5217/ir.2022.00030","DOIUrl":"https://doi.org/10.5217/ir.2022.00030","url":null,"abstract":"<p><strong>Background/aims: </strong>The study objective is to investigate the ultrasound features that allow suspecting the presence of submucosal fat deposition, called the fat halo sign (FHS), in the intestinal wall of patients with Crohn's disease.</p><p><strong>Methods: </strong>Computed tomography (CT) examinations over a period of 10 years were reviewed for the presence of the FHS in the bowel wall. A measurement of less than -10 Hounsfield units was regarded as indicative of fat. We included only patients who had undergone ultrasound examinations 3 months before or after CT. The study cohort group comprised 68 patients. Wall and submucosal thickness were measured on longitudinal ultrasound sections. A receiver operating characteristic curve was constructed to determine the best cutoff of ultrasound submucosal wall thickness value for predicting FHS in the bowel wall determined on CT.</p><p><strong>Results: </strong>The FHS was present in 22 patients (31%) on CT. There were significant differences between submucosal thickness of patients with FHS and patients without FHS (4.19 mm vs. 2.41 mm). From the receiver operating characteristic curve, a threshold value of 3.1 mm of submucosal thickness had the best sensitivity and specificity to suspect FHS (95.5% and 89.1%, respectively; area under the curve, 0.962), with an odds ratio of 172. All of 16 patients with a submucosal thickness >3.9 mm had FHS.</p><p><strong>Conclusions: </strong>FHS in patients with Crohn's disease can be suspected on ultrasound in cases with marked thickening of the submucosa layer. In these cases, the activity of the disease should be measured by other parameters such as the color Doppler.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":"21 3","pages":"385-391"},"PeriodicalIF":4.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/7a/ir-2022-00030.PMC10397555.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9992800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory bowel disease (IBD)-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD.","authors":"Arshdeep Singh,&nbsp;Yogesh Kumar Gupta,&nbsp;Ashvin Singh Dhaliwal,&nbsp;Bhavjeet Kaur Kahlon,&nbsp;Vasu Bansal,&nbsp;Ramit Mahajan,&nbsp;Varun Mehta,&nbsp;Dharmatma Singh,&nbsp;Ramandeep Kaur,&nbsp;Namita Bansal,&nbsp;Vandana Midha,&nbsp;Ajit Sood","doi":"10.5217/ir.2022.00037","DOIUrl":"https://doi.org/10.5217/ir.2022.00037","url":null,"abstract":"<p><strong>Background/aims: </strong>The inflammatory bowel disease (IBD)-disk is a validated, visual, 10-item, self-administered questionnaire used to evaluate IBD-related disability. The present study aimed to evaluate IBD-disk in assessment of IBD daily life burden and its relation with disease activity.</p><p><strong>Methods: </strong>A cross-sectional study was conducted between June 2021 and December 2021. Patients with IBD were asked to complete the IBD-disk and a visual analogue scale of IBD daily-life burden (scored from 0-10, score >5 indicative of high burden). The internal consistency of IBD-disk, correlation with IBD daily life burden and disease activity (assessed by partial Mayo score and Harvey Bradshaw Index in patients with ulcerative colitis [UC] and Crohn's disease [CD], respectively) and diagnostic performance of IBD-disk to detect high burden were analyzed.</p><p><strong>Results: </strong>Out of the 546 patients (mean age 40.33±13.74 years, 282 [51.6%] males) who completed the IBD-disk, 464 (84.98%) had UC and the remaining (n=82, 15.02%) had CD. A total of 311 patients (291 UC and 20 CD; 56.95%) had active disease. The mean IBD-disk total score and IBD daily life burden were 18.39±15.23 and 2.45±2.02, respectively. The IBD-disk total score correlated strongly with the IBD daily life burden (ρ=0.94, P<0.001), moderately with partial Mayo score (ρ=0.50) and weakly with Harvey Bradshaw Index (ρ=0.34). The IBD-disk total score >30 predicted high IBD daily-life burden.</p><p><strong>Conclusions: </strong>The IBD-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD and can be applied in clinical practice. (Intest Res, Published online).</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":"21 3","pages":"375-384"},"PeriodicalIF":4.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/22/ir-2022-00037.PMC10397543.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9937561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}